Trial
NCT04493333
Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Arkansas
Collaborators
AMAG Pharmaceuticals, Inc.
Condition
Vaginal Atrophy
Intervention
Vaginal Dehydroepiandrosterone
Why stopped
Low recruitment/enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-11-27